Benitec Biopharma Stock (NASDAQ:BNTC), Trade Ideas

Benitec Biopharma

Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.

pharma lab worker ai

Biotech

Equities

News

Health Care

Movers

Trading Ideas

General

BNTC

Latest clinical data on BB-301 treatment for OPMD. Positive results in swallowing improvement. Benitec Biopharma announces interim findings and $40 million PIPE financing.

Why Is Gene Therapy Developer Benitec Biopharma Stock Trading Higher On Thursday?

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

ASLE

AXLA

CJJD

DFLI

FRGT

GMVD

HALL

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

IFBD

MDIA

SLGG

SXTC

Gainers


	Axcella Health Inc. (NASDAQ: AXLA) shares gained 65% to $0.2887 in pre-market trading after gaining 12% on Monday. The company recently posted a narrower-than-expected quarterly loss.


Why ProMIS Neurosciences Shares Are Trading Higher By 33%; Here Are 20 Stocks Moving Premarket

Intraday Update

AGTI

AKAN

ANGI

ARRY

ASNS

AVXL

AXON

AZTA

BGLC

BIRD

BLFS

BOOM

BROS

BRSH

CELH

CUTR

DBTX

DKNG

DOCS

DRUG

DXPE

EBET

EGHT

ELBM

EMKR

EXFY

FTCI

IDAI

INFI

ISPO

KBNT

KVHI

LPRO

LPSN

LPTV

LYFT

MGIH

MRTX

MVIS

NOTE

NRDY

NVEI

OFIX

OPRT

PALI

PLAG

PMTS

PMVP

PSTX

PUBM

RBLX

RENB

SCPL

SEER

SMCI

SNCE

Sony Group Corporation American Depositary Shares

SONY

SOUN

TBLA

TDUP

TLRY

TNGX

TOST

TWOU

TYGO

UIHC

UPST

VERI

Gainers


	Tango Therapeutics, Inc. (NASDAQ: TNGX) climbed 85.2% to $7.09 after gaining 11% on Tuesday. Tango Therapeutics recently posted a narrower quarterly loss.


Why Cutera Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Wednesday&#39;s Session

Benitec Biopharma Inc

JMP Securities analyst Silvan Tuerkcan maintains Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) with a Market Outperform and raises the price target from $10 to $16.

Price Target

Analyst Ratings

JMP Securities Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $16

<h3>Gainers</h3>
<ul>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) stock moved upwards by 9.0% to $4.58 during Thursday's after-market session. The company's market cap stands at $3.4 million. </li>
<li>Biora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOR#NASDAQ">BIOR</a>) shares moved upwards by 8.4% to $0.65. The market value of their outstanding shares is at $23.2 million. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) shares rose 7.78% to $0.4. The market value of their outstanding shares is at $4.1 million. </li>
<li>BIMI Intl Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIMI#NASDAQ">BIMI</a>) shares moved upwards by 7.46% to $1.44. The market value of their outstanding shares is at $20.1 million. </li>
<li>Allarity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLR#NASDAQ">ALLR</a>) stock increased by 7.14% to $1.65. The company's market cap stands at $3.2 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) stock rose 6.06% to $1.05. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) stock decreased by 18.2% to $3.2 during Thursday's after-market session. The company's market cap stands at $3.7 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) stock fell 11.17% to $0.37. The company's market cap stands at $3.3 million. </li>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares declined by 9.39% to $0.22. The market value of their outstanding shares is at $4.3 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock declined by 8.76% to $0.04. The company's market cap stands at $4.4 million. </li>
<li>Cyclo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTH#NASDAQ">CYTH</a>) shares decreased by 7.5% to $1.11. The market value of their outstanding shares is at $31.8 million. </li>
<li>Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) shares decreased by 6.16% to $6.4. The company's market cap stands at $16.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLR

BIMI

BIOR

BPTH

CYTH

ISPC

MBIO

PRTG

SINT

VRPX

12 Health Care Stocks Moving In Thursday's After-Market Session

Thursday,&nbsp;Benitec Biopharma Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) released interim clinical data from the 90-day timepoint following the administration of BB-301 to the study&#8217;s first subject (Subject 1) treated in the BB-301 Phase 1b/2a study in&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/g38310794/benitec-biopharma-reports-positive-interim-clinical-trial-data-for-first-opmd-subject-treated-with" rel="noreferrer noopener">Oculopharyngeal Muscular Dystrophy</a>&nbsp;(OPMD).
&#8220;To date, no clinical studies have systematically demonstrated a clinical improvement in OPMD patients across both objective and subjective measures of swallowing. We are, therefore, pleased to report positive interim clinical data from multiple radiographic measures as well as subject-reported outcome measures from the first subject treated with BB-301,&#8221; said Jerel Banks, Executive Chairman and Chief Executive Officer of Benitec.&nbsp;
During the OPMD Natural History Study, which represents the pre-dose observational period for each subject, Subject 1 experienced progressive worsening of dysphagia (difficulty swallowing) as demonstrated by the results of the videofluoroscopic swallowing studies (VFSS), the cold water timed drinking test.
At the 90-day timepoint following the administration of BB-301, Subject 1 demonstrated improvements in key videofluoroscopic assessments.
The results of many assessments completed at the 90-day timepoint demonstrated improvements over the initial measurements assessed at the subject&#8217;s first visit for the natural history observational study, which occurred more than 12 months before the 90-day assessment.
The most significant VFSS improvements at Day 90 were observed for swallowing tasks centered on evaluating pharyngeal constrictor muscle function and swallowing efficiency in consuming thin liquids, solid foods, and thick, non-solid foods.&nbsp;
So far, no severe side effects have been noted in the safety profile of BB-301. Two subjects experienced temporary Grade 2 (mild) Gastroesophageal Reflux Disease (GERD), which was treated with standard prescription medication.
OPMD is a rare progressive muscle-wasting disease caused by a poly(A)-binding protein nuclear 1 gene mutation. The disease is characterized by swallowing difficulties (dysphagia), limb weakness, and eyelid drooping (ptosis). Dysphagia worsens over time.
Concurrently, Benitec Biopharma announced a $40 million private investment in public equity (PIPE) financing from the sale of 5.7 million shares at $4.80/share and in lieu of shares of common stock, pre-funded warrants to purchase up to an aggregate of 2.58 million shares at a price per pre-funded warrant of $4.7999, to<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/g38310080/benitec-biopharma-announces-oversubscribed-private-placement-financing-of-40-0-million" rel="noreferrer noopener">&nbsp;certain institutional accredited investors.</a>
Price Action: BNTC shares are up 24% at $5.95 on the last check Thursday.
Illustration of Phrama lab worker created with MidJourney.

<h3>Gainers</h3>
<ul>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) stock moved upwards by 67.1% to $5.42 during Thursday's regular session. The market value of their outstanding shares is at $4.0 million. </li>
<li>Aileron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALRN#NASDAQ">ALRN</a>) stock moved upwards by 53.88% to $6.54. The company's market cap stands at $111.0 million. As per the press release, Q4 earnings came out 3 days ago. </li>
<li>23andMe Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) stock moved upwards by 45.48% to $0.52. The company's market cap stands at $250.2 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock moved upwards by 40.75% to $0.05. The company's market cap stands at $6.4 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares moved upwards by 33.19% to $0.28. The company's market cap stands at $2.5 million. </li>
<li>Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) shares moved upwards by 25.62% to $6.03. The market value of their outstanding shares is at $15.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SeaStar Medical Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>) stock decreased by 27.0% to $0.51 during Thursday's regular session. The company's market cap stands at $38.4 million. As per the news, the Q4 earnings report came out 2 days ago. </li>
<li>Aptorum Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) stock declined by 26.35% to $5.34. The company's market cap stands at $29.2 million. </li>
<li>NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) stock fell 25.12% to $3.13. The market value of their outstanding shares is at $29.9 million. </li>
<li>Genetic Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GENE#NASDAQ">GENE</a>) stock fell 23.74% to $2.41. The market value of their outstanding shares is at $9.2 million. </li>
<li>Ontrak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) stock fell 20.39% to $0.29. The market value of their outstanding shares is at $13.8 million. As per the press release, Q4 earnings came out 2 days ago. </li>
<li>INVO Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVO#NASDAQ">INVO</a>) stock decreased by 20.34% to $1.45. The market value of their outstanding shares is at $3.9 million. The company's, Q4 earnings came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALRN

GENE

INVO

NRXP

OTRK

12 Health Care Stocks Moving In Thursday's Intraday Session

Benitec Biopharma Shares Halted On Circuit Breaker To The Upside, Stock Now Up 29%

BPTH: 98% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/38311088">Bio-Path Holdings shares are trading higher after the company announced the completion of its second dose cohort in Phase 1/1b clinical trial of BP1002 evaluating the ability of BP1002 to treat refractory/relapsed acute myeloid leukemia patients</a>
THCH: 47% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/38311386">TH International shares are trading higher after the company reported a year-over-year increase in Q4 financial results.</a>
BNTC: 60% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/38311141">Benitec Biopharma shares are trading higher. The company announced a $40 million oversubscribed private placement financing and reported interim clinical data for the first OPMD subject treated with BB-301 in its Phase 1b/2a study.</a>

THCH

Market-Moving News for April 18th

<h3>Gainers</h3>
<ul>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares increased by 43.8% to $4.66 during Thursday's pre-market session. The market value of their outstanding shares is at $3.5 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares moved upwards by 39.41% to $0.05. The company's market cap stands at $6.3 million. </li>
<li>23andMe Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) stock moved upwards by 26.61% to $0.45. The company's market cap stands at $217.7 million. </li>
<li>Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) shares rose 25.62% to $6.03. The company's market cap stands at $15.6 million. </li>
<li>Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) stock moved upwards by 22.86% to $0.49. The company's market cap stands at $9.0 million. </li>
<li>Citius Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) stock moved upwards by 16.38% to $0.95. The company's market cap stands at $151.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) shares declined by 22.5% to $3.24 during Thursday's pre-market session. The company's market cap stands at $31.0 million. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) stock decreased by 17.61% to $0.42. The market value of their outstanding shares is at $4.4 million. </li>
<li>Sonoma Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) stock declined by 13.75% to $0.14. The company's market cap stands at $2.2 million. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) shares fell 11.12% to $0.34. The company's market cap stands at $3.5 million. </li>
<li>Dynatronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYNT#NASDAQ">DYNT</a>) stock fell 10.26% to $0.53. The market value of their outstanding shares is at $2.5 million. </li>
<li>SeaStar Medical Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>) shares decreased by 9.46% to $0.63. The company's market cap stands at $47.7 million. As per the press release, Q4 earnings came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTXR

DYNT

SNGX

SNOA

TRVN

12 Health Care Stocks Moving In Thursday's Pre-Market Session

WIIM

Benitec Biopharma shares are trading higher. The company announced a $40 million oversubscribed private placement financing and reported interim clinical data for the first OPMD subject treated with BB-301 in its Phase 1b/2a study.

Benitec Biopharma Reports Interim Clinical Trial Data For First OPMD Subject Treated With BB-301 In Phase 1b/2a Study; Says 'BB-301 facilitated improvements across multiple measures of swallowing function in the first Phase 1b/2a clinical study subject as compared to pretreatment assessments conducted during the observational natural history portion of the study'

Benitec Biopharma&nbsp;announced a&nbsp;$40.0&nbsp;million&nbsp;private investment in public equity (PIPE) financing from the sale of 5.749 million shares of its common stock at a price per share of&nbsp;$4.80, and, in lieu of shares of common stock,&nbsp;pre-funded&nbsp;warrants to purchase up to an aggregate of 2.58 million shares of its common stock at a price per&nbsp;pre-funded&nbsp;warrant of&nbsp;$4.7999, to certain institutional accredited investors.&nbsp;Gross proceeds from the PIPE financing total approximately&nbsp;$40.0&nbsp;million, before deducting offering expenses.
The Company intends to use the net proceeds from the PIPE financing to fund the clinical development and related commercialization of BB-301, including the natural history lead-in study and the Phase 1b/2a BB-301 treatment study, and for general corporate purposes.

Offerings

Benitec Biopharma Reports Oversubscribed Private Placement Financing Of $40M

<h3>Gainers</h3>
<ul>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) shares rose 55.0% to $3.1 during Monday's regular session. The company's market cap stands at $105.6 million. </li>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) stock moved upwards by 54.8% to $0.14. The market value of their outstanding shares is at $6.9 million. </li>
<li>Ainos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIMD#NASDAQ">AIMD</a>) shares increased by 39.99% to $1.47. The company's market cap stands at $6.8 million. </li>
<li>Renalytix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) shares moved upwards by 36.52% to $1.42. The market value of their outstanding shares is at $70.9 million. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFW#NASDAQ">LIFW</a>) shares increased by 25.04% to $1.29. The market value of their outstanding shares is at $19.0 million. </li>
<li>Jin Medical International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJYL#NASDAQ">ZJYL</a>) stock rose 24.68% to $7.93. The market value of their outstanding shares is at $1.2 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock decreased by 42.6% to $1.08 during Monday's regular session. The company's market cap stands at $43.2 million. </li>
<li>Vivani Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VANI#NASDAQ">VANI</a>) stock fell 20.12% to $2.47. The market value of their outstanding shares is at $125.9 million. </li>
<li>First Wave BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWBI#NASDAQ">FWBI</a>) stock declined by 19.49% to $7.44. The market value of their outstanding shares is at $11.6 million. </li>
<li>FibroBiologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBLG#NASDAQ">FBLG</a>) shares fell 19.24% to $10.5. The market value of their outstanding shares is at $341.1 million. </li>
<li>BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) stock fell 18.89% to $0.47. The market value of their outstanding shares is at $12.1 million. </li>
<li>Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) stock decreased by 17.89% to $4.62. The company's market cap stands at $11.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIMD

BCDA

BIVI

FBLG

FWBI

JAGX

LIFW

OCEA

RNLX

VANI

ZJYL

12 Health Care Stocks Moving In Monday's Intraday Session

Benitec Biopharma Files For Mixed Shelf Of Up To $125M

JMP Securities analyst Silvan Tuerkcan maintains Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) with a Market Outperform and raises the price target from $8 to $10.

JMP Securities Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $10

Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) reported quarterly losses of $(2.64) per share. This is a 20.96 percent increase over losses of $(3.34) per share from the same period last year.

Earnings

Benitec Biopharma Q2 EPS $(2.64) Up From $(3.34) YoY

JMP Securities analyst Silvan Tuerkcan maintains Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) with a Market Outperform and raises the price target from $6 to $8.

JMP Securities Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $8

Benitec Biopharma Has Dosed The First Subject In The BB-301 Gene Therapy Phase 1B/2A Trial For Oculopharyngeal Muscular Dystrophy-related Dysphagia

Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) reported quarterly losses of $(2.76) per share. This is a 65.46 percent increase over losses of $(7.99) per share from the same period last year.

Benitec Biopharma Q1 EPS $(2.76) Up From $(7.99) YoY

JMP Securities analyst Silvan Tuerkcan maintains Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) with a Market Outperform and raises the price target from $4 to $6.

JMP Securities Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $6

Benitec Biopharma Releases Full Year 2023 Financial Results And Provides Operational Update; FY23 EPS $(14.12) Vs $(37.88) YoY; Revenue $75K Vs $73K YoY;

<h3>Gainers</h3>
<ul>
<li>Axcella Health Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axla#NASDAQ">AXLA</a>) shares gained 65% to $0.2887 in pre-market trading after gaining 12% on Monday. The company recently posted a narrower-than-expected quarterly loss.</li>
<li>ProMIS Neurosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pmn#NASDAQ">PMN</a>) shares surged 32.9% to $2.10 in pre-market trading. ProMIS Neurosciences announced a $20.4 million private placement financing at $1.88 per unit.</li>
<li>G Medical Innovations Holdings Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gmvd#NASDAQ">GMVD</a>) rose 26.4% to $0.1995 in pre-market trading.</li>
<li>Freight Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/frgt#NASDAQ">FRGT</a>) rose 22.1% to $0.6094 in pre-market trading after gaining around 4% on Monday.</li>
<li>Hallmark Financial Services, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hall#NASDAQ">HALL</a>) shares rose 21.8% to $3.57 in pre-market trading. Hallmark Financial recently posted a second-quarter operating loss of $6.83 per share.</li>
<li>FLJ Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flj#NASDAQ">FLJ</a>) shares gained 19.9% to $0.2278 in pre-market trading. FLJ Group is expected to hold its 2023 annual general meeting on Sept. 18, 2023.</li>
<li>Benitec Biopharma Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bntc#NASDAQ">BNTC</a>) shares climbed 18.5% to $3.33 in pre-market trading. Benitec Biopharma 13G filing showed Citadel Advisors LLC holds 6.9% stake in the company.</li>
<li>Super League Gaming, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/slgg#NASDAQ">SLGG</a>) shares rose 16.4% to $0.14 in pre-market trading after falling around 50% on Monday. Super League announced pricing of $2.2 million underwritten public offering of 16,923,077 shares of common stock at $0.13 per share.</li>
<li>Infobird Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ifbd#NASDAQ">IFBD</a>) gained 14.6% to $0.3150 in pre-market trading.</li>
<li>AerSale Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asle#NASDAQ">ASLE</a>) gained 11% to $14.02 in pre-market trading. AerSale completed certification flight testing for AerAware Enhanced Flight Vision System (EFVS).</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Tingo Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tio#NASDAQ">TIO</a>) fell 31.4% to $0.8126 in pre-market trading. Tingo Group said it further postponed its second-quarter earnings release and filing of its form 10-Q for the period ended June 30, 2023.</li>
<li>MediaCo Holding Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdia#NASDAQ">MDIA</a>) shares fell 16.7% to $0.62 in pre-market trading after gaining more than 30% on Monday.</li>
<li>China SXT Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sxtc#NASDAQ">SXTC</a>) shares fell 16.2% to $0.2011 in pre-market trading after gaining 60% on Monday.</li>
<li>Dragonfly Energy Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dfli#NASDAQ">DFLI</a>) fell 15.8% to $1.62 in pre-market after the company reported downbeat second-quarter results and issued weak forecast for the third quarter.</li>
<li>SOS Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sos#NYSE">SOS</a>) fell 14.1% to $7.69 in pre-market trading after jumping over 99% on Monday.</li>
<li>PureCycle Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pct#NASDAQ">PCT</a>) fell 11.7% to $8.72 in pre-market trading after announcing private offering of $200.0 million of green convertible senior notes.</li>
<li>MicroCloud Hologram Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/holo#NASDAQ">HOLO</a>) shares fell 8.2% to $4.12 in pre-market trading after surging 32% on Monday.</li>
<li>Emergent BioSolutions Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ebs#NYSE">EBS</a>) fell 8.2% to $4.37 in pre-market trading. Advance Auto Parts will replace Emergent BioSolutions in the S&amp;P SmallCap 600, effective Aug. 25.</li>
<li>Ucommune International Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/uk#NASDAQ">UK</a>) fell 7.7% to $0.2821 in pre-market trading after gaining 12% on Monday.</li>
<li>China Jo-Jo Drugstores, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cjjd#NASDAQ">CJJD</a>) fell 6.9% to $0.3152 in pre-market trading after gaining 21% on Monday.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/23/08/33977703/lowes-dicks-sporting-goods-and-3-stocks-to-watch-heading-into-tuesday"> Lowe&#39;s, Dick&#39;s Sporting Goods And 3 Stocks To Watch Heading Into Tuesday </a>

Benitec Biopharma Ltd (BNTC) just unveiled an update. Benitec Biopharma Inc. has awarded its CEO, Dr. Jerel Banks, and Executive Director, Megan Bo...

Benitec Biopharma Awards Stock Options to Top Executives

Catalyst Watch: Boeing hearing, Bitcoin halving event and new eyes on Reddit

Netflix, Johnson & Johnson, Procter & Gamble And Baidu On Watch

Wall Street Breakfast: The Week Ahead

Benitec Biopharma jumps 33% on $40M private financing

Benitec Biopharma reports positive data in early study for OPMD treatment

An update from Benitec Biopharma Ltd (BNTC) is now available. Benitec Biopharma Inc. announced promising interim results from its BB-301 Phase 1b/2...

Benitec Biopharma Showcases Encouraging Clinical Trial Results

CGC, GENE and HOLO among mid-day movers

An update from Benitec Biopharma Ltd (BNTC) is now available. Benitec Biopharma Inc. has entered into a Securities Purchase Agreement on April 17, ...

Benitec Biopharma's $40 Million Equity Financing Deal

In a report released today, Silvan Tuerkcan from JMP Securities reiterated a Buy rating on Benitec Biopharma (BNTC – Research Report), with a price...

Buy Rating Affirmed for Benitec Biopharma Following Promising BB-301 Trial Results and Financial Boost